Daniel Schneiderman

Insider Reports History

Location
Brooklyn, NY
Signature
/s/ Daniel Schneiderman
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Daniel Schneiderman:

Company Role Class Num Shares Value Price $ Report Date Ownership
Pasithea Therapeutics Corp. Chief Financial Officer Common Stock 26,667 $20,000 $0.7500 28 Nov 2025 Direct
Pasithea Therapeutics Corp. Chief Financial Officer Stock Option (right to buy) 317,266 24 Oct 2025 Direct
First Wave BioPharma, Inc. CHIEF FINANCIAL OFFICER Stock option (right to buy) 10,000 03 Jan 2022 Direct

Insider Reports Filed by Daniel Schneiderman

Symbol Company Period Transactions Value $ Form Type Role Filing Time
KTTA Pasithea Therapeutics Corp. 28 Nov 2025 1 +$20,000 4 Chief Financial Officer 01 Dec 2025, 09:04
KTTA Pasithea Therapeutics Corp. 24 Oct 2025 1 $0 4 Chief Financial Officer 27 Oct 2025, 17:27
KTTA Pasithea Therapeutics Corp. 01 Mar 2024 2 $0 4/A Chief Financial Officer 05 Apr 2024, 21:45
KTTA Pasithea Therapeutics Corp. 01 Mar 2024 2 $0 4 Chief Financial Officer 01 Mar 2024, 21:46
KTTA Pasithea Therapeutics Corp. 11 Oct 2022 1 $0 4 Chief Financial Officer 12 Oct 2022, 20:15
KTTA Pasithea Therapeutics Corp. 12 Aug 2022 0 $0 3 Interim Chief Accting Officer 15 Aug 2022, 20:51
ENTO First Wave BioPharma, Inc. 03 Jan 2022 1 $0 4 CHIEF FINANCIAL OFFICER 03 Jan 2022, 20:07
ENTO AzurRx BioPharma, Inc. 30 Jun 2021 4 $0 4 CHIEF FINANCIAL OFFICER 02 Jul 2021, 17:09